-
公开(公告)号：US07452875B2
公开(公告)日：2008-11-18
申请号：US11833430
申请日：2007-08-03
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： C07D223/16 , A61K38/05 , A61P9/12
CPC分类号： C07D223/16 , C07D401/12 , C07K5/0222 , C07K5/06139
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
-
22.发明授权Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them 有权酰胺甲基取代的1-（羧基烷基）环戊基 - 羰基氨基 - 苯并氮杂-N-乙酸化合物，其制备方法和中间产物以及含有它们的药物组合物公开(公告)号：US07410962B2
公开(公告)日：2008-08-12
申请号：US11773231
申请日：2007-07-03
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： C07D223/16 , A61K38/05 , A61P9/12
CPC分类号： C07K5/06139 , C07K5/0222
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
摘要翻译： 具有对应于式I的中性内肽酶（NEP）和/或人可溶内肽酶（hSEP）抑制活性的化合物，其中取代基R 1，R 2，R SUP > 3和R 4具有说明书中给出的含义，并且还含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或不利条件的药物组合物 与凋亡相关。
-
23.发明申请AMIDOMETHYL-SUBSTITUTED 1-(CARBOXYALKYL) CYCLOPENTYL-CARBONYLAMINO-BENZAZEPINE-N-ACETIC ACID COMPOUNDS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 有权氨基取代的1-（羧基甲基）环戊烯基 - 亚磺酰氨基 - 苯甲腈-N-乙酸化合物，其制备和其包含它们的药物组合物的方法和中间产物公开(公告)号：US20070265244A1
公开(公告)日：2007-11-15
申请号：US11773231
申请日：2007-07-03
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： A61K31/55 , A61P9/00 , C07D487/00
CPC分类号： C07K5/06139 , C07K5/0222
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
摘要翻译： 具有对应于式I的中性内肽酶（NEP）和/或人可溶内肽酶（hSEP）抑制活性的化合物，其中取代基R 1，R 2，R SUP > 3和R 4具有说明书中给出的含义，并且还含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或不利条件的药物组合物 与凋亡相关。
-
公开(公告)号：US20050130979A1
公开(公告)日：2005-06-16
申请号：US11043219
申请日：2005-01-26
申请人： Lechoslaw Turski , Terence Smith
发明人： Lechoslaw Turski , Terence Smith
IPC分类号： C07D243/02 , A61K31/00 , A61K31/225 , A61K31/35 , A61K31/40 , A61K31/4245 , A61K31/437 , A61K31/47 , A61K31/4725 , A61K31/473 , A61K31/4745 , A61K31/498 , A61K31/4985 , A61K31/5025 , A61K31/513 , A61K31/517 , A61K31/549 , A61K31/551 , A61K31/662 , A61K31/675 , A61K38/00 , A61K38/17 , A61K45/06 , A61P25/00 , A61P25/02 , A61P25/28 , C07D207/44 , C07D215/22 , C07D217/26 , C07D239/91 , C07D239/92 , C07D241/38 , C07D241/44 , C07D285/24 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D471/04 , C07D487/04 , C07D487/12 , C07D491/056 , C07D498/04 , C07D513/04 , C07D517/04
CPC分类号： A61K31/7048 , A61K31/00 , A61K31/225 , A61K31/35 , A61K31/4245 , A61K31/4725 , A61K31/4745 , A61K31/498 , A61K31/4985 , A61K31/513 , A61K31/517 , A61K31/551 , A61K31/675 , A61K38/17 , A61K45/06
摘要： This invention is directed to pharmaceutical compositions and methods for treating demyelinating disorders based upon inhibitors of the interaction of glutamate with the AMPA and of the interaction of glutamate with the kainite receptor complex.
-
25.发明授权Quinoxalinedione derivatives, their production and use in pharmaceutical agents 失效喹喔啉二酮衍生物，其生产和用于药剂
公开(公告)号：US5750525A
公开(公告)日：1998-05-12
申请号：US537839
申请日：1996-03-08
申请人： Andreas Huth , Lechoslaw Turski
发明人： Andreas Huth , Lechoslaw Turski
IPC分类号： A61K31/495 , A61K31/498 , A61K31/66 , A61K31/675 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/28 , C07D241/44 , C07D401/12 , C07D403/06 , C07D521/00 , C07F9/6509 , C07F9/6558 , C07D241/36 , C07D413/00 , C07D417/00
CPC分类号： C07D231/12 , C07D233/56 , C07D241/44 , C07D249/08 , C07D401/12 , C07D403/06 , C07F9/650994 , C07F9/65583
摘要： Compounds of formula I are described ##STR1## in which R.sup.1, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 have the meanings mentioned in the application as well as their production and use in pharmaceutical agents.
摘要翻译： PCT No.PCT / DE94 / 00493 Sec。 371日期：1996年3月8日 102（e）1996年3月8日PCT PCT 1994年4月28日PCT公布。 公开号WO94 / 25469 日期：1994年11月10日化学式Ⅰ的化合物描述为其中R 1，R 5，R 6，R 7和R 8具有本申请中提及的含义及其在制药中的用途。
-
26.发明申请Amidomethyl-Substituted 1-(Carboxyalkyl) Cyclopentyl-Carbonylamino-Benzazepine-N-Acetic Acid Compounds, Process and Intermediate Products for Their Preparation and Pharmaceutical Compositions Containing Them 有权酰基甲基取代的1-（羧基烷基）环戊基 - 羰基氨基 - 苯并氮杂-N-乙酸化合物，其制备方法和中间体产品及含有它们的药物组合物公开(公告)号：US20080085889A1
公开(公告)日：2008-04-10
申请号：US11833430
申请日：2007-08-03
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： A61K31/55 , A61P25/28 , C07D487/00
CPC分类号： C07D223/16 , C07D401/12 , C07K5/0222 , C07K5/06139
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
摘要翻译： 具有对应于式I的中性内肽酶（NEP）和/或人可溶内肽酶（hSEP）抑制活性的化合物，其中取代基R 1，R 2，R SUP > 3和R 4具有说明书中给出的含义，并且还含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或不利条件的药物组合物 与凋亡相关。
-
27.发明授权Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them 有权酰胺甲基取代的1-（羧基烷基）环戊基 - 羰基氨基 - 苯并氮杂-N-乙酸化合物，其制备方法和中间产物以及含有它们的药物组合物公开(公告)号：US07262184B2
公开(公告)日：2007-08-28
申请号：US10948843
申请日：2004-09-24
申请人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
发明人： Dagmar Hoeltje , Yvan Fischer , Dieter Ziegler , Michael Weske , Katrin Michaelis , Yasmin Karimi-Nejad , Josef Messinger , Axel Pahl , Constanze Hoefer , Hrissanthi Ikonomidou , Lechoslaw Turski
IPC分类号： C07D223/16 , A61P9/12 , A61K38/05
CPC分类号： C07K5/06139 , C07K5/0222
摘要： Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula 1, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
摘要翻译： 具有对应于式1的中性内肽酶（NEP）和/或人可溶内肽酶（hSEP）抑制活性的化合物，其中取代基R 1，R 2，R SUP > 3和R 4具有在说明书中给出的含义，并且还含有这些化合物的药物组合物，特别是适用于治疗或抑制心血管疾病，性功能障碍和/或不利条件的药物组合物 与凋亡相关。
-
28.发明申请AMPA antagonists for the treatment of dizziness, including vertigo and Meniere's disorder 审中-公开AMPA拮抗剂用于治疗眩晕，包括眩晕和梅尼尔氏症公开(公告)号：US20060166969A1
公开(公告)日：2006-07-27
申请号：US11331026
申请日：2006-01-13
IPC分类号： A61K31/551
CPC分类号： A61K31/551
摘要： The disclosure relates to the use of 8,9-dimethyl-5-phenyl-11H-1,3-dioxolo[4,5-h]-imidazo[1,2-c][2,3]benzodiazepine: prodrugs, tautomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of the foregoing, for the preparation of a pharmaceutical composition for the treatment, amelioration or prevention of dizziness, including vertigo and Menière's disorder.
摘要翻译： 本公开涉及使用8,9-二甲基-5-苯基-11H-1,3-二氧杂环戊烯并[4,5-h] - 咪唑并[1,2-c] [2,3]苯并二氮杂：前药，互变异构体 和N-氧化物，以及上述的药理学上可接受的盐，水合物和溶剂合物，用于制备用于治疗，改善或预防头晕的药物组合物，包括眩晕和梅尼埃病。
-
公开(公告)号：US20050182047A1
公开(公告)日：2005-08-18
申请号：US11043732
申请日：2005-01-26
申请人： Lechoslaw Turski , Terence Smith
发明人： Lechoslaw Turski , Terence Smith
IPC分类号： C07D243/02 , A61K31/00 , A61K31/225 , A61K31/35 , A61K31/40 , A61K31/4245 , A61K31/437 , A61K31/47 , A61K31/4725 , A61K31/473 , A61K31/4745 , A61K31/498 , A61K31/4985 , A61K31/5025 , A61K31/513 , A61K31/517 , A61K31/549 , A61K31/551 , A61K31/662 , A61K31/675 , A61K38/00 , A61K38/17 , A61K45/06 , A61P25/00 , A61P25/02 , A61P25/28 , C07D207/44 , C07D215/22 , C07D217/26 , C07D239/91 , C07D239/92 , C07D241/38 , C07D241/44 , C07D285/24 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D471/04 , C07D487/04 , C07D487/12 , C07D491/056 , C07D498/04 , C07D513/04 , C07D517/04 , A61K31/5513
CPC分类号： A61K31/7048 , A61K31/00 , A61K31/225 , A61K31/35 , A61K31/4245 , A61K31/4725 , A61K31/4745 , A61K31/498 , A61K31/4985 , A61K31/513 , A61K31/517 , A61K31/551 , A61K31/675 , A61K38/17 , A61K45/06
摘要： This invention is directed to pharmaceutical compositions and methods for treating demyelinating disorders based upon inhibitors of the interaction of glutamate with the AMPA and of the interaction of glutamate with the kainite receptor complex.
摘要翻译： 本发明涉及基于谷氨酸与AMPA相互作用的抑制剂以及谷氨酸与卡培酮受体复合物的相互作用的治疗脱髓鞘疾病的药物组合物和方法。
-
公开(公告)号：US5385903A
公开(公告)日：1995-01-31
申请号：US910873
申请日：1992-07-09
IPC分类号： A61K31/495 , A61K31/55 , A61K31/66 , A61K45/00 , A61K45/06 , A61P25/30 , A61P43/00 , A61K31/675
CPC分类号： A61K45/06 , A61K31/495 , A61K31/66 , Y10S514/812
摘要： The use of the non-NMDA receptor antagonists quisqualate or kainate antagonists or their physiologically compatible salts for treatment of withdrawal symptoms after drug abuse as well as the combination of the new pharmaceutical agents with NMDA antagonists are described.
摘要翻译： 描述了使用非NMDA受体拮抗剂quisqualate或kainate拮抗剂或其生理上相容的盐来治疗药物滥用之后的戒断症状以及新药物与NMDA拮抗剂的组合。
-
-
-
-
-
-
-
-
-
搜索结果
31 条记录 (耗时 0.036 秒)
